Ironwood Pharmaceuti(IRWD-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low4.37
Day High4.65
Open:4.62
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Zacks Investment Research
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Zacks Investment Research
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Tipranks
Ironwood Pharma Shareholders Reaffirm Board and Governance Structure
Tipranks
Ironwood Pharma Strengthens Balance Sheet With Note Repayment
Tipranks
Ironwood Pharmaceuticals Signals Blockbuster Momentum in 2026
Motley Fool
Ironwood (IRWD) Q1 2026 Earnings Call Transcript
Tipranks
Analysts’ Top Healthcare Picks: Ironwood Pharma (IRWD), Sionna Therapeutics, Inc. (SION)
Tipranks
Ironwood Pharma Announces CFO Resignation and Interim Successor
MarketBeat
Ironwood Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat.com
Tipranks
Analysts Conflicted on These Healthcare Names: Dexcom (DXCM), Ironwood Pharma (IRWD) and Crispr Therapeutics AG (CRSP)
Motley Fool
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential
Tipranks
Craig-Hallum Sticks to Its Buy Rating for Ironwood Pharma (IRWD)
Tipranks
Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Opus Genetics (IRD)
Tipranks
Ironwood Pharma Maintains Revolving Credit Facility to 2028
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Delcath Systems (DCTH), Viridian Therapeutics (VRDN)
Motley Fool
Ironwood (IRWD) Q4 2025 Earnings Call Transcript
Tipranks
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Ironwood Pharma (IRWD)
MarketBeat
3 Stocks Trading Near $5 With Massive Earnings Upside
MarketBeat.com
Zacks Investment Research
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics

Profile

Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.